Compare USNA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | MRVI |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.3M | 472.8M |
| IPO Year | 1996 | 2020 |
| Metric | USNA | MRVI |
|---|---|---|
| Price | $21.43 | $3.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $36.00 | $4.57 |
| AVG Volume (30 Days) | 112.4K | ★ 1.1M |
| Earning Date | 02-17-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $912,670,000.00 | $192,435,000.00 |
| Revenue This Year | $10.42 | N/A |
| Revenue Next Year | $3.37 | $10.00 |
| P/E Ratio | $23.59 | ★ N/A |
| Revenue Growth | ★ 5.88 | N/A |
| 52 Week Low | $18.48 | $1.67 |
| 52 Week High | $38.32 | $4.77 |
| Indicator | USNA | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 34.58 |
| Support Level | $20.57 | $3.06 |
| Resistance Level | $21.98 | $3.51 |
| Average True Range (ATR) | 0.79 | 0.18 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 47.74 | 5.35 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.